Quanterix Corporation (QTRX)
Quanterix Corporation is a life sciences company specializing in digital immunoassay platforms for precision health research and diagnostics. Their Simoa technology enables highly sensitive protein detection across various therapeutic areas.
Company Overview
Quanterix is revolutionizing precision health with its Simoa technology, enabling ultra-sensitive protein detection for life science research and diagnostics, positioning them as a key player in neurology, oncology, and other critical therapeutic areas, though profitability remains a key challenge.
Investment Thesis
Quanterix presents a compelling investment opportunity due to its leading-edge Simoa technology, which enables highly sensitive protein detection with applications across multiple high-growth therapeutic areas. The company's focus on precision health positions it favorably within the evolving healthcare landscape. Key value drivers include continued adoption of the HD-X and SR-X platforms, expansion of the assay menu, and strategic partnerships with pharmaceutical and diagnostic companies. The company's gross margin of 51.1% indicates strong pricing power. Upcoming catalysts include potential FDA approvals for diagnostic assays and expansion into new geographic markets. However, investors should be aware of the company's current negative profit margin of -74.2% and the need to achieve profitability to ensure long-term sustainability. The current market capitalization of $0.28 billion may offer an attractive entry point, assuming the company can execute its growth strategy and improve its financial performance.
Key Highlights
- Market capitalization of $0.28 billion, reflecting its position as a key player in the precision health market.
- Gross margin of 51.1%, indicating strong pricing power in its niche market.
- Beta of 1.07, suggesting stock price volatility is similar to the overall market.
- P/E ratio of -2.93, reflecting current losses but potential for future earnings growth.
- Operates in high-growth therapeutic areas including neurology, oncology, cardiology, infectious diseases, and inflammation.
Competitors
Strengths
- Proprietary Simoa technology with high sensitivity.
- Strong presence in key therapeutic areas.
- Established customer base and distribution network.
- Recurring revenue from assay kits and consumables.
Weaknesses
- Currently unprofitable with a negative profit margin.
- Reliance on a limited number of key products.
- High operating expenses related to R&D and sales.
- Competition from established players in the diagnostics market.
Catalysts
- Upcoming: Potential FDA approvals for diagnostic assays.
- Ongoing: Expansion of the assay menu and applications.
- Ongoing: Strategic partnerships with pharmaceutical and diagnostic companies.
- Ongoing: Geographic expansion into emerging markets.
Risks
- Ongoing: Unprofitability and need to achieve positive earnings.
- Potential: Competition from established players in the diagnostics market.
- Potential: Regulatory hurdles and changing reimbursement policies.
- Potential: Technological obsolescence.
- Potential: Economic downturn impacting research funding.
Growth Opportunities
- Expansion of Assay Menu: Quanterix has the opportunity to significantly expand its assay menu, targeting a broader range of biomarkers and therapeutic areas. This includes developing assays for neurodegenerative diseases like Alzheimer's and Parkinson's, as well as oncology and infectious disease applications. The market for biomarker assays is estimated to reach billions of dollars, and Quanterix's Simoa technology provides a competitive advantage in developing highly sensitive and specific assays. Timeline: Ongoing, with new assays being released regularly.
- Strategic Partnerships: Forming strategic partnerships with pharmaceutical and diagnostic companies can accelerate the adoption of Quanterix's technology and expand its market reach. These partnerships can involve co-development of assays, joint marketing efforts, or integration of Quanterix's platform into diagnostic workflows. The market for partnering with diagnostic companies is substantial, driven by the need for innovative technologies and access to new markets. Timeline: Ongoing, with potential for new partnerships to be announced in the near term.
- Geographic Expansion: Quanterix has the opportunity to expand its geographic footprint, particularly in emerging markets where demand for advanced diagnostics is growing rapidly. This includes expanding its sales and support infrastructure in regions like Asia-Pacific and Latin America. The market for diagnostics in emerging markets is projected to grow at a faster rate than in developed markets, presenting a significant growth opportunity for Quanterix. Timeline: Ongoing, with phased expansion plans.
- Direct Detection of Nucleic Acids: Leveraging the SR-X instrument to directly detect nucleic acids opens new avenues for applications beyond protein detection. This capability can be applied in areas such as infectious disease diagnostics and liquid biopsy for cancer detection. The market for nucleic acid detection is substantial and growing, driven by the increasing use of molecular diagnostics. Timeline: Ongoing, with further development and commercialization efforts.
- FDA Approval of Diagnostic Assays: Obtaining FDA approval for its diagnostic assays would significantly enhance Quanterix's credibility and expand its market access. This would allow the company to market its assays for clinical use, opening up new revenue streams and opportunities for growth. The market for FDA-approved diagnostic assays is substantial, driven by the increasing demand for reliable and accurate diagnostic tests. Timeline: Dependent on regulatory processes, with potential approvals in the coming years.
Opportunities
- Expansion of assay menu and applications.
- Strategic partnerships with pharmaceutical and diagnostic companies.
- Geographic expansion into emerging markets.
- FDA approval of diagnostic assays.
Threats
- Competition from alternative diagnostic technologies.
- Regulatory hurdles and changing reimbursement policies.
- Potential for technological obsolescence.
- Economic downturn impacting research funding.
Competitive Advantages
- Proprietary Simoa technology enables ultra-sensitive protein detection.
- Strong intellectual property portfolio protecting its technology.
- Established customer base in key research and diagnostic markets.
- High switching costs due to the specialized nature of its platform.
About
Quanterix Corporation, formerly Digital Genomics, Inc., was founded in 2007 and is headquartered in Billerica, Massachusetts. The company is focused on transforming healthcare through its innovative digital immunoassay platforms. These platforms, based on its proprietary Simoa (Single Molecule Array) technology, enable the ultra-sensitive detection of proteins, providing researchers and clinicians with unprecedented insights into disease biology. Quanterix offers a range of instruments, including the HD-X, a fully automated, high-throughput platform; the SR-X, designed for broader application of Simoa technology; and the SP-X, based on Simoa planar array technology. These instruments are complemented by a comprehensive suite of assay kits and consumables, catering to diverse research and diagnostic needs. Quanterix operates across several key therapeutic areas, including neurology, oncology, cardiology, infectious diseases, and inflammation. The company serves a global customer base, including academic and governmental research institutions, pharmaceutical and biotechnology companies, and contract research organizations. Quanterix utilizes a direct sales force, support organizations, and distributors to reach its customers. While Quanterix holds a strong position in the precision health space, it currently faces challenges in achieving profitability, as reflected in its negative profit margin.
What They Do
- Develops and markets digital immunoassay platforms.
- Offers instruments for ultra-sensitive protein detection.
- Provides assay kits and consumables for research and diagnostics.
- Offers contract research services, including sample testing.
- Develops custom assays for specific research needs.
- Focuses on neurology, oncology, cardiology, infectious diseases, and inflammation.
Business Model
- Sells instruments (HD-X, SR-X, SP-X) to research and diagnostic labs.
- Generates recurring revenue through the sale of assay kits and consumables.
- Provides contract research services to pharmaceutical and biotech companies.
- Forms strategic partnerships for assay development and commercialization.
Industry Context
Quanterix operates within the medical devices industry, a segment experiencing growth driven by technological advancements and increasing demand for precision diagnostics. The market for immunoassay platforms is competitive, with key players focusing on improving sensitivity, throughput, and automation. Quanterix differentiates itself through its Simoa technology, which offers significantly higher sensitivity compared to traditional immunoassays. Competitors include companies like CVRX, IMRX, INGN, MASS and NNOX, some of whom offer alternative diagnostic solutions. The overall market for precision medicine is projected to continue growing, fueled by advancements in genomics, proteomics, and data analytics. Quanterix is well-positioned to capitalize on this trend with its innovative platform and expanding assay menu.
Key Customers
- Academic and governmental research institutions.
- Pharmaceutical and biotechnology companies.
- Contract research organizations (CROs).
- Diagnostic laboratories.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40M | -$34M | $-0.73 |
| Q2 2025 | $24M | -$30M | $-0.77 |
| Q1 2025 | $30M | -$21M | $-0.53 |
| Q4 2024 | $34M | -$12M | $-0.30 |
Source: Company filings
Chart & Info
Price Chart
Quanterix Corporation (QTRX) stock price: $5.79 (+0.00, +0.00%)
Why Bull
- •Quanterix's recent insider buying suggests strong confidence from those closest to the company's operations, mirroring situations like Palantir in early 2021 where insider activity preceded a notable uptrend.
- •The social trading community shows increasing optimism around Quanterix's Simoa technology, seeing its potential in early disease detection as a game-changer. Think Illumina's early days, where innovative tech drove investor excitement.
- •Positive buzz indicates growing market perception of Quanterix as a key player in precision health, potentially attracting more institutional interest. Similar to how CRISPR Therapeutics gained traction for its gene-editing breakthroughs.
- •The community is actively discussing potential partnerships and expansions, fueling speculation about future growth opportunities for Quanterix, reminiscent of early Amazon discussions around new market entries.
Why Bear
- •Recent community concerns highlight that Quanterix's market adoption is slower than anticipated, raising questions about its commercialization strategy. This mirrors concerns around Fitbit's initial adoption rates.
- •Some insiders sold shares, which, while not necessarily bearish, prompts caution in the community, similar to post-IPO lockup expirations where insider selling can create downward pressure.
- •The social trading community expresses worries about increasing competition in the diagnostics sector, potentially impacting Quanterix's market share. This is akin to the challenges faced by GoPro as action camera competition intensified.
- •Negative sentiment suggests some investors are becoming impatient with the company's path to profitability, drawing parallels to the skepticism surrounding early-stage biotech companies before major breakthroughs.
Latest News
-
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing
Simply Wall St. · Feb 14, 2026
-
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing
Yahoo! Finance: QTRX News · Feb 14, 2026
-
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Zacks · Feb 4, 2026
-
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Yahoo! Finance: QTRX News · Feb 4, 2026
Technical Analysis
Rationale
AI-generated technical analysis for QTRX including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Quanterix Corporation (QTRX) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for QTRX.
Make a Prediction
Set your price target for Quanterix Corporation (QTRX), choose a timeframe, and track your prediction accuracy.
Current price: $5.79
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QTRX.
Price Targets
Median: $8.00 (+38.2% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 11.8% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 8/100
Gross margin at 51.1% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 6/100
Adequate cash of $57M covers near-term needs but may require additional funding for aggressive expansion.
-
R&D Intensity 10/100
Investing 22.9% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 1.57% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates QTRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test
Frequently Asked Questions
What does Quanterix Corporation do?
Quanterix Corporation is a life sciences company that develops and markets digital immunoassay platforms based on its proprietary Simoa technology. These platforms enable the ultra-sensitive detection of proteins in biological samples, providing researchers and clinicians with valuable insights into disease biology. The company's products include instruments, assay kits, and consumables, which are used in a variety of applications, including neurology, oncology, cardiology, infectious diseases, and inflammation. Quanterix generates revenue through the sale of its products and services to academic institutions, pharmaceutical companies, and contract research organizations. The company aims to transform healthcare by providing more accurate and sensitive diagnostic tools.
Is QTRX stock a good buy?
QTRX stock presents a mixed investment profile. The company's innovative Simoa technology and strong position in the precision health market are attractive, as is the gross margin of 51.1%. However, the company's current unprofitability, with a negative profit margin of -74.2%, raises concerns. Potential investors should carefully consider the company's growth prospects, its ability to achieve profitability, and the competitive landscape. While the current market capitalization of $0.28 billion may offer an attractive entry point, the stock is best suited for investors with a high-risk tolerance and a long-term investment horizon. Monitoring the company's progress in expanding its assay menu, securing strategic partnerships, and improving its financial performance is crucial.
What are the main risks for QTRX?
The main risks for Quanterix include its current unprofitability and the need to achieve positive earnings, as the negative profit margin of -74.2% is a significant concern. The company also faces competition from established players in the diagnostics market, who may have greater resources and market share. Regulatory hurdles and changing reimbursement policies could also impact the company's ability to commercialize its products. Additionally, there is a risk of technological obsolescence, as new diagnostic technologies may emerge that could render Quanterix's platform less competitive. An economic downturn could also negatively impact research funding and demand for the company's products and services. Careful monitoring of these risks is essential for investors.
Is QTRX a good stock to buy?
Whether QTRX is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the QTRX MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is QTRX data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for QTRX?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Quanterix Corporation.
Who are QTRX's main competitors?
Quanterix Corporation's competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how QTRX compares.
What do analysts say about QTRX?
Analyst ratings and price targets for QTRX are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is QTRX's market cap?
Market capitalization reflects the total market value of QTRX's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has QTRX stock performed recently?
Check the Chart & Info tab for QTRX's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in QTRX?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for QTRX-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling QTRX?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for QTRX.
Is QTRX a good stock for beginners?
Quanterix Corporation (QTRX) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is QTRX for first-time investors?
Every stock carries risk, including Quanterix Corporation (QTRX). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like QTRX.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update. Financial data is based on the most recently available information.
- This analysis is for informational purposes only and should not be considered investment advice.